Factual data · GO/NO-GO verdict · Financial model calibrated over 96 months
A pharmacy in Oslo generates 2.3M NOK-7M NOK NOK revenue, with net margin of 8 %. Typical mix: 75-85 % prescription drugs (regulated margin), 15-25 % OTC/wellness (free margin 35-45 %).
Dominant profile: business · capitale
Oslo (Oslo, Norway) has about 697K inhabitants and shows dense business fabric (HQs, B2B services, professionals), and capital-city status (administration, embassies, official events) smoothing off-season demand. For a pharmacy project, this means a high average ticket and a setup cost above national by 60 %.
Local purchasing power and lead density allow targeting the high end of the revenue range from year 2. Concretely, initial investment calibrated for Oslo ranges from 1.3M NOK to 5.6M NOK, and Year 1 target revenue sits between 2.3M NOK and 7M NOK — a range that already factors in the local coefficients of this city (+60% vs average on costs, +55% vs average on purchasing power).
Competitive density: high (dense supply, segmentation required).
Dominant players: regulated public-insurance sector, few private chains.
Positioning recommendation: Competitive positioning required: sector margin is tight, edge comes from operational efficiency.
| Indicator | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Year 1 revenue | 2.3M NOK → 7M NOK | ×1,18 (ramp-up) | ×1,32 (steady-state) |
| Target net margin | negative to low | 4 % | 10 % |
| Working capital (days of revenue) | 45-60 d | 35-50 d | 30-45 d |
| Cumulative ROI | investment | ~50 % | Payback at 96 months |
These ratios are calibrated on MarketLens sector benchmarks and adjusted by local coefficients of Oslo, Norway (cost +60% vs average, income +55% vs average).
This page combines multiple data sources for a factual analysis calibrated on Oslo.
MarketLens combines AI market study, business plan calibrated for 24 countries, and post-launch monitoring. Everything exportable to PDF, PowerPoint, Excel and Word.